Cargando…

Overcoming Heterogeneity of Antigen Expression for Effective CAR T Cell Targeting of Cancers

Chimeric antigen receptor (CAR) gene-modified T cells (CAR T cells) can eradicate B cell malignancies via recognition of surface-expressed B lineage antigens. Antigen escape remains a major mechanism of relapse and is a key barrier for expanding the use of CAR T cells towards solid cancers with thei...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kailayangiri, Sareetha, Altvater, Bianca, Wiebel, Malena, Jamitzky, Silke, Rossig, Claudia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281243/ https://www.ncbi.nlm.nih.gov/pubmed/32357417 http://dx.doi.org/10.3390/cancers12051075

Ejemplares similares

Carbohydrate Targets for CAR T Cells in Solid Childhood Cancers
por: Rossig, Claudia, et al.
Publicado: (2018)

Surface expression of the immunotherapeutic target G(D2) in osteosarcoma depends on cell confluency
por: Wiebel, Malena, et al.
Publicado: (2021)

The Cellular Tumor Immune Microenvironment of Childhood Solid Cancers: Informing More Effective Immunotherapies
por: Holterhus, Malcolm, et al.
Publicado: (2022)

HLA-G and HLA-E Immune Checkpoints Are Widely Expressed in Ewing Sarcoma but Have Limited Functional Impact on the Effector Functions of Antigen-Specific CAR T Cells
por: Altvater, Bianca, et al.
Publicado: (2021)

T cell infiltration into Ewing sarcomas is associated with local expression of immune-inhibitory HLA-G
por: Spurny, Christian, et al.
Publicado: (2017)

CAR T cells as micropharmacies against solid cancers: Combining effector T-cell mediated cell death with vascular targeting in a one-step engineering process
por: Altvater, Bianca, et al.
Publicado: (2023)

Relevance of Abnormal KCNN1 Expression and Osmotic Hypersensitivity in Ewing Sarcoma
por: Fuest, Sebastian, et al.
Publicado: (2022)

The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting
por: Kailayangiri, S, et al.
Publicado: (2012)

CAR T Cell Therapy in Glioblastoma: Overcoming Challenges Related to Antigen Expression
por: Luksik, Andrew S., et al.
Publicado: (2023)

Variable Expression of the Disialoganglioside GD2 in Breast Cancer Molecular Subtypes
por: Erber, Ramona, et al.
Publicado: (2021)

Design and Characterization of an “All-in-One” Lentiviral Vector System Combining Constitutive Anti-G(D2) CAR Expression and Inducible Cytokines
por: Zimmermann, Katharina, et al.
Publicado: (2020)

GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD(2) and Releasing Inducible IL-18
por: Glienke, Wolfgang, et al.
Publicado: (2022)

Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies
por: Kyriakidis, Ioannis, et al.
Publicado: (2021)

S79. CAR strategies in solid tumours
por: Rossig, C
Publicado: (2014)

Ewing sarcoma dissemination and response to T-cell therapy in mice assessed by whole-body magnetic resonance imaging
por: Liebsch, L, et al.
Publicado: (2013)

Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma
por: Larson, Rebecca C., et al.
Publicado: (2023)

Targeting CD10 on B-Cell Leukemia Using the Universal CAR T-Cell Platform (UniCAR)
por: Mitwasi, Nicola, et al.
Publicado: (2022)

Generation of an NFκB-Driven Alpharetroviral “All-in-One” Vector Construct as a Potent Tool for CAR NK Cell Therapy
por: Rudek, Loreen Sophie, et al.
Publicado: (2021)

Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma
por: García-Guerrero, Estefanía, et al.
Publicado: (2020)

Unifying heterogeneous expression data to predict targets for CAR-T cell therapy
por: Schreiner, Patrick, et al.
Publicado: (2021)

SS18-SSX drives CREB activation in synovial sarcoma
por: Cyra, Magdalene, et al.
Publicado: (2022)

Immune modulation by molecular cancer targets and targeted therapies: Rationale for novel combination strategies
por: Rossig, Claudia
Publicado: (2012)

A Novel CAR Expressing NK Cell Targeting CD25 With the Prospect of Overcoming Immune Escape Mechanism in Cancers
por: Dehbashi, Moein, et al.
Publicado: (2021)

CAR T-Cell Cancer Therapy Targeting Surface Cancer/Testis Antigens
por: Jakobsen, Mie K., et al.
Publicado: (2020)

Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment
por: van der Schans, Jort J., et al.
Publicado: (2020)

Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma
por: Martínez Bedoya, Darel, et al.
Publicado: (2021)

Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity
por: Ma, Leyuan, et al.
Publicado: (2023)

Stressed target cancer cells drive nongenetic reprogramming of CAR T cells and tumor microenvironment, overcoming multiple obstacles of CAR T therapy for solid tumors
por: Wang, Yufeng, et al.
Publicado: (2023)

The IAP antagonist birinapant enhances chimeric antigen receptor T cell therapy for glioblastoma by overcoming antigen heterogeneity
por: Song, Edward Z., et al.
Publicado: (2022)

CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing
por: Andersch, Lena, et al.
Publicado: (2019)

Targeting gastrointestinal cancers with chimeric antigen receptor (CAR)-T cell therapy
por: Staudt, Ross E, et al.
Publicado: (2022)

Anti-CD19 CARs displayed at the surface of lentiviral vector particles promote transduction of target-expressing cells
por: Cordes, Nicole, et al.
Publicado: (2021)

An optimized bicistronic chimeric antigen receptor against GPC2 or CD276 overcomes heterogeneous expression in neuroblastoma
por: Tian, Meijie, et al.
Publicado: (2022)

Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies
por: Sun, Shangjun, et al.
Publicado: (2018)

Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion
por: Gumber, Diana, et al.
Publicado: (2022)

Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy
por: Lv, Zixin, et al.
Publicado: (2023)

Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure
por: Smith, Michael P, et al.
Publicado: (2017)

In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy
por: Xin, Tianqing, et al.
Publicado: (2022)

“UniCAR”-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells
por: Mitwasi, Nicola, et al.
Publicado: (2020)

Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13Rα2 are effective against heterogeneous glioblastoma
por: Schmidts, Andrea, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hlcad5aia7nf1k468u7dgv5ea5